BCTX:NSD-BriaCell Therapeutics Corp (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.84

Change

+0.28 (+6.14)%

Market Cap

USD 0.08B

Volume

0.23M

Avg Analyst Target

USD 25.00 (+416.53%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BriaCell Therapeutics Corp (BCTX) Stock Analysis:
Based on the BriaCell Therapeutics Corp stock forecasts from 1 analysts, the average analyst target price for BriaCell Therapeutics Corp is USD 25.00 over the next 12 months. BriaCell Therapeutics Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BriaCell Therapeutics Corp is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, BriaCell Therapeutics Corp’s stock price was USD 4.84. BriaCell Therapeutics Corp’s stock price has changed by +2.76% over the past week, -31.73% over the past month and +53.65% over the last year.

About

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatmen ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+4.86 (+0.71%)

USD74.91B 9.70 7.18
VRTX Vertex Pharmaceuticals Incorpo..

+2.36 (+0.88%)

USD68.63B 28.32 19.22
MRNA Moderna Inc

-1.21 (-0.92%)

USD54.74B 4.05 2.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+0.17 (+0.11%)

USD39.61B 3.12 1.86
RPRX Royalty Pharma plc

+0.47 (+1.18%)

USD27.00B 29.25 15.23
SGEN Seagen Inc

+3.00 (+2.25%)

USD25.65B 55.02 44.86
GMAB Genmab A/S

-0.53 (-1.74%)

USD20.43B 60.76 5.35
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ARGX argenx SE

+3.30 (+1.05%)

USD17.25B N/A N/A

ETFs Containing BCTX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -41.55% 59% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.55% 59% F 30% F
Trailing 12 Months  
Capital Gain 54.14% 98% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.14% 98% A+ 97% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 23.18% 69% D+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.18% 68% D+ 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 50.71% 57% F 29% F
Risk Adjusted Return 45.71% 83% B 74% C
Market Capitalization 0.08B 38% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 10.38 44% F 67% D+
Price/Book Ratio 1.51 57% F 53% F
Price / Cash Flow Ratio -9.94 81% B- 77% C+
EV/EBITDA 53.43 5% F 12% F
Management Effectiveness  
Return on Equity -27.28% 80% B- 32% F
Return on Invested Capital -26.23% 78% C+ 29% F
Return on Assets -32.19% 36% F 11% F
Debt to Equity Ratio 0.05% 91% A- 91% A-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.15 83% B 74% C
Short Percent 19.89% 6% F 8% F
Beta 1.63 34% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.